GC Genome Shares Fall 5.81% to 8,600 Won... Samsung Securities: "U.S. Early Pancreatic Cancer Diagnosis Results Are Key"
GC Genome fell more than 5% intraday on the 3rd, dropping into the 8,000-won range. Amid securities firm assessments that the company is securing profitability through growth in domestic prenatal testing and non-covered cancer testing services, attention is focused on the future progress of its U.S.

GC Genome fell more than 5% intraday on the 3rd, dropping into the 8,000-won range. Amid securities firm assessments that the company is securing profitability through growth in domestic prenatal testing and non-covered cancer testing services, attention is focused on the future progress of its U.S. early pancreatic cancer diagnosis business.
■ Share Price Movement In the morning trading session on the 3rd, GC Genome was trading at 8,600 won, down 530 won from the previous trading day. This represents a 5.81% decline compared to the previous day's closing price of 9,130 won.
■ Samsung Securities Assessment... Domestic Business in a Profitability-Securing Phase Samsung Securities assessed that GC Genome is sustaining growth while securing profitability based on the growth of its domestic prenatal testing business and the non-covered iCANSERCH service. In the domestic business, prenatal testing and cancer-related testing services were cited as the main growth foundations. In particular, the growth trend of iCANSERCH, a non-covered testing service, is said to be contributing to securing profitability.
However, Samsung Securities pointed out that growth in the domestic business alone would not be enough to close the valuation gap with global peers, and that additional achievements are needed.
■ Key Variable Is the U.S. Early Pancreatic Cancer Diagnosis Business The key lies in the U.S. early pancreatic cancer diagnosis business. Samsung Securities analyzed that for GC Genome to narrow its valuation gap with global peers, it is important to secure a credible business partner in the U.S. market. It also cited accumulating data through prospective clinical trials as an essential condition.
A prospective clinical trial is a method of collecting necessary data by tracking study subjects over a certain period, and it can be used to evaluate the performance of early diagnosis technology. This means that, along with building partnerships in the U.S. business, how much clinical evidence the company secures could influence its future valuation.
■ Future Points to Watch While growth and profitability securing through the domestic testing business are currently underway, the U.S. early pancreatic cancer diagnosis business is evaluated as being at a stage where additional achievements need to be confirmed. With GC Genome's share price having fallen to 8,600 won, whether the company secures a partner for its U.S. business and the process of accumulating prospective clinical data remain key items to watch.
[This article was written based on intraday share prices and securities firm analysis, and does not recommend buying or selling any specific stock. The progress of the U.S. business and clinical results may change depending on future announcements. Stock investment carries the risk of principal loss, and investment decisions and responsibility rest with the investor. AI provided partial assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



